Evommune Statistics
Total Valuation
Evommune has a market cap or net worth of $658.70 million. The enterprise value is $572.67 million.
| Market Cap | 658.70M |
| Enterprise Value | 572.67M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Evommune has 30.08 million shares outstanding.
| Current Share Class | 30.08M |
| Shares Outstanding | 30.08M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +1.30% |
| Owned by Insiders (%) | 2.75% |
| Owned by Institutions (%) | 5.63% |
| Float | 14.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 93.96 |
| Forward PS | n/a |
| PB Ratio | 7.68 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 190.89 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.40, with a Debt / Equity ratio of 0.01.
| Current Ratio | 9.40 |
| Quick Ratio | 8.60 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3,618.86 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -88.25% |
| Revenue Per Employee | $66,667 |
| Profits Per Employee | -$1.47M |
| Employee Count | 45 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 61.46 |
| Average Volume (20 Days) | 93,106 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Evommune had revenue of $3.00 million and -$66.26 million in losses. Loss per share was -$5.15.
| Revenue | 3.00M |
| Gross Profit | 3.00M |
| Operating Income | -76.00M |
| Pretax Income | -64.76M |
| Net Income | -66.26M |
| EBITDA | -74.55M |
| EBIT | -76.00M |
| Loss Per Share | -$5.15 |
Balance Sheet
The company has $86.80 million in cash and $771,000 in debt, giving a net cash position of $86.02 million or $2.86 per share.
| Cash & Cash Equivalents | 86.80M |
| Total Debt | 771,000 |
| Net Cash | 86.02M |
| Net Cash Per Share | $2.86 |
| Equity (Book Value) | 85.77M |
| Book Value Per Share | -12.93 |
| Working Capital | 84.80M |
Cash Flow
| Operating Cash Flow | -94.85M |
| Capital Expenditures | n/a |
| Free Cash Flow | -94.85M |
| FCF Per Share | -$3.15 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -2,533.20% |
| Pretax Margin | -2,158.80% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Evommune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -10.06% |
| FCF Yield | -14.40% |
Analyst Forecast
The average price target for Evommune is $39.33, which is 79.59% higher than the current price. The consensus rating is "Buy".
| Price Target | $39.33 |
| Price Target Difference | 79.59% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Evommune has an Altman Z-Score of -4.14. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.14 |
| Piotroski F-Score | n/a |